• 1
    Nauck, M. A. (1998) Glucagon-like peptide 1 (GLP-1): a potent gut hormone with possible therapeutic perspective. Acta Diabetol 35: 117129.
  • 2
    Drucker, D. J. (2001) Minireview: the glucagon-like peptides. Endocrinology 142: 521527.
  • 3
    Meier, J. J., Gallwitz, B., Schmidt, W. E., Nauck, M. A. (2002) Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives. Eur J Pharmacol. 440: 269279.
  • 4
    Shimizu, I., Hirota, M., Ohboshi, C., Shima, K. (1987) Identification and localization of glucagon-like peptide-1 and its receptor in rat brain. Endocrinology 121: 10761082.
  • 5
    Lambert, P. D., Wilding, J. P. H., Ghatei, M. A., Bloom, S. R. (1993) A role for GLP-1(7–36)NH2 in the central control of feeding behaviour. Digestion 54(Suppl 1): 360361.
  • 6
    Schick, R. R., Zimmermann, J. P., vorm Walde, T., Schusdziarra, V., Classen, M. (1992) Glucagon-like-peptide (GLP)-1-(7-36)-amide: a central suppressor of food intake in rats. Gastroenterology 102(Suppl 1): A756
  • 7
    Turton, M. D., O'shea, D., Gunn, I., et al. (1996) A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379: 6972.
  • 8
    Donahey, J. C., van Dijk, G., Woods, S. C., Seeley, R. J. (1998) Intraventricular GLP-1 reduces short- but not long-term food intake or body weight in lean and obese rats. Brain Res. 779: 7583.
  • 9
    Kieffer, T. J., McIntosh, C. H. S., Pederson, R. A. (1995) Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136: 35863596.
  • 10
    de Fonseca, F. Rodriguez, Navarro, M., Alvarez, E., et al. (2000) Peripheral versus central effects of glucagon-like peptide-1 receptor agonist on satiety and body weight loss in Zucker obese rats. Metabolism 49: 709717.
  • 11
    De Menthiere, C. Sarrauste, Chavanieu, A., et al. (2004) Structural requirements of the N-terminal region of GLP-1-[7–37]-NH(2) for receptor interaction and cAMP production. Eur J Med Chem 39: 473480.
  • 12
    Al-Barazanji, K. A., Arch, J. R. S., Buckingham, R. E., Tadayyon, M. (2000) Central exendin-4 infusion reduces body weight without altering plasma leptin in (fa/fa) Zucker rats. Obes Res. 8: 267323.
  • 13
    Szayna, M., Doyle, M. E., Betkey, J. A., et al. (2000) Exendin-4 decelerated food intake, weight gain and fat deposition in Zucker rats. Endocrinology 141: 19361941.
  • 14
    Larson, P. J., Fledelius, C., Knudsen, L. B., Tang-Christensen, M. (2001) Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes 50: 25302539.
  • 15
    Young, A. A., Gedulin, B. R., Bhavsar, S., et al. (1999) Glucose lowering and insulin-sensitizing actions of exendin-4. Diabetes 48: 10261034.
  • 16
    Claret, M., Corominola, H., Casamitjana, R., Gomis, R. (2001) Tungstate treatment reduces body weight in diet-induced obesity. Diabetologia 44(Suppl 1): A182
  • 17
    Meeran, K., O'shea, D., Edwards, C. M. B., et al. (1999) Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat. Endocrinology 140: 244250.
  • 18
    Thiele, T. E., Van Dijk, G., Campfield, L. A., et al. (1997) Central infusión of GLP-1, but not leptin, produces conditioned taste aversions in rats. Am J Physiol. 272: R726R730.
  • 19
    Mizuno, A., Kuwajima, M., Ishida, K., et al. (1997) Extrapancreatic action of truncated glucagon-like peptide-1 in Otsuka Long-Evans Tokushima fatty rats, an animal model for non-insulin-dependent diabetes mellitus. Metabolism 46: 745749.
  • 20
    Olefsky, J. M., Saltiel, A. R. (2000) PPARγ and the treatment of insulin resistance. Trends Endocrinol Metab. 11: 362368.
  • 21
    Claire, M., Lazar, M. A. (2002) Resistin and obesity-associated insulin resistance. Trends Endocrinol Metab. 13: 1823.
  • 22
    Redonnet, A., Groubet, R., Noel-Suberville, C., Bonilla, S., Martinez, A., Higueret, P. (2001) Exposure to an obesity-inducing diet early affects the pattern of expression of peroxisome proliferator, retinoic acid, and triiodothyronine nuclear receptors in the rat. Metabolism 50: 11611167.
  • 23
    Ukkola, O. (2002) Resistin—a mediator of obesity-associated insulin resistance or an innocent bystander? Eur J Endocrinol. 147: 571574.
  • 24
    Nakazato, M., Murakami, N., Date, Y., et al. (2001) A role for ghrelin in the central regulation of feeding. Nature 409: 194198.
  • 25
    Toshinai, K., Mondal, M. S., Nakazato, M., et al. (2001) Upregulation of ghrelin expression in the stomach upon fasting, insulin-induced hypoglycemia, and leptin administration. Biochem Biophys Res Commun. 281: 12201225.
  • 26
    O'shea, D., Gunn, I., Chen, X., Bloom, S., Herbert, J. A. (1996) A role for central glucagon-like peptide-1 in temperature regulation. Neuroreport 7: 830832.
  • 27
    Hwa, J. J., Ghibaudi, L., Williams, P., Witten, M. B., Tedesco, R., Strader, C. D. (1998) Differential effects of intracerebroventricular glucagon-like peptide-1 on feeding and energy expenditure regulation. Peptides 19: 869875.
  • 28
    Schick, R. R., Zimmermann, J. P., vorm Walde, T., Schusdziarra, V. (2003) Glucagon-like peptide 1-(7-36) amide acts at lateral and medial hypothalamic sites to supress feeding in rats. Am J Physiol. 284: R1427R1435.
  • 29
    Kastin, A. J., Akerstrom, V., Pan, W. (2002) Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J Mol Neurosci. 18: 714.
  • 30
    Hassan, M., Eskilsson, A., Nilsson, C., et al. (1999) In vivo dynamic distribution of 131I-Glucagon-like peptide-1 (7–36) amide in the rat studied by gamma camera. Nucl Med Biol. 26: 413420.
  • 31
    Kastin, A. J., Akerstrom, V. (2003) Entry of exendin-4 into brain is rapid but may be limited at high doses. Int J Obes Relat Metab Disord. 27: 313318.
  • 32
    Orskov, C., Poulsen, S. S., Moller, M., Holst, J. J. (1996) Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I. Diabetes 45: 832835.